Background This study aims to: (1) document the prevalence of hepatitis C virus (HCV) among methadone maintenance treatment (MMT) patients in Kunming and Shanghai; (2) examine risk factors for HCV by comparing those who tested positive with those who were negative and (3) examine if HCV serostatus is related to attitudes toward MMT.
Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide.
1,2 HCV is a blood-borne virus that is easily transmitted and has been identified as the most common viral infection affecting injection drug users (IDUs). 3 Most opiate use is by injection and China is prominent among world regions with the largest numbers and highest concentration of injection opiate users infected with HCV diseases. 4, 5 Current policies and resources in China have focused on HIV, as in most other countries. Specifically, the recent nationwide implementation of methadone maintenance treatment (MMT) in China has been a response to the rapid spread of HIV/AIDS. 6 -8 Nevertheless, the high prevalence and potential adverse consequences of HCV require greater attention. 9 The present article examines HCV issues among patients in MMT in China, who are mostly injection heroin addicts and thus at high risks for HCV infection, transmission and related health consequences.
In China, drug abuse increased dramatically in the 1980s and spread throughout the country; drug addiction and related problems are now among the greatest challenges facing the country. According to the Office of China National Narcotic Control Commission, the cumulative number of registered drug users in China increased from 70 000 in 1990 to 956 000 in 2007, of which 749 000 were registered as heroin users. 10 Given that in 2007, the population of China reached 1.318 billion, it is estimated that in the same year the rate of registered heroin users was 56.8 per 100 000. The actual number of drug addicts is estimated to have reached 3.5 million. At least 75-85% of registered drug addicts use heroin and 50-70% of heroin users inject the drug. Injection drug use is now the predominant mode of HCV transmission, with HCV prevalence ranging from 11% (Shannxi) to 91% (Hubei) among IDUs. 8 The pooled average of reported HCV-positive rates among Chinese IDUs was 60 3 -67%. 8 A large body of international research has shown the efficacy of MMT for the treatment of opiate addiction and subsequent reduction in HIV risk behaviors. As a strategy for addressing the escalating HIV problem, the Chinese government set up the first eight MMT clinics in early 2004. By the end of 2009, China had opened more than 500 MMT clinics. The rapidly expanded program signals that the Chinese government understands the critical link between drug use and control of HIV/AIDS. As part of the routine intake procedure, all patients admitted to MMT are tested for HCV, in addition to HIV and other medical conditions. To test for HCV infection, MMT programs in China routinely utilize screening tests for antibody to HCV (anti-HCV).
The literature on HCV and related issues in China has been limited, and even fewer studies have addressed HCV among Chinese IDUs. Existing studies have generally demonstrated that many IDUs do not know their HCV status, 11, 12 that HCV knowledge is poor among IDUs 13 -16 and that access to HCV services is limited. 14, 15 The lack of knowledge about HCV may prevent these IDUs from implementing measures that could reduce their risk of contracting the virus, thereby increasing the likelihood of transmission to others. 16 Factors associated with HCV seroprevalence identified in the literature among Chinese IDUs include older age, injection drug use, shared needles or syringes, syphilis infection and concomitant use of other drugs. 5, 17, 18 Considering the large number of IDUs in China and rapid transmission of HCV among and beyond this population, HCV is one of the China's major health burdens. The present study examined the relationships between HCV status with knowledge about HCV and risk behaviors. Given that MMT is an important harm reduction strategy for a high-risk population in China, we also examined the HCV status in relation to attitudes toward MMT among Chinese MMT patients. The study objectives were: (1) to document the prevalence of HCV among MMT patients; (2) to examine the risk factors for HCV by comparing those who tested positive with those who were negative, including HCV knowledge and risk behaviors such as drug use, injection use and sexual risk behaviors and (3) to examine if HCV serostatus is related to attitudes toward MMT.
Methods

Study participants
As part of a larger study investigating MMT outcomes in China, patients were recruited from consecutive admissions to MMT programs in Shanghai and Kunming during 2009 and 2010. The aim of this parent study was to apply and test if a contingency management intervention could improve treatment retention and reduce drug use. The study was conducted in two sites: (1) Shanghai, the most populous and developed urban city in China, has 13 million permanent residents and 4 million transient residents. Subject eligibility criteria included opiate dependence (according to the criteria established by the Diagnostic and Statistical Manual IV), at least 20 years of age or older and being local residents. Participants were not required to be sober and study activities were conducted by professionally trained clinical staff either just before or after participants received methadone treatment. All participants provided informed consent and were paid for their time. Study participants were asked to respond to questions involving their socio-demographics, risk behaviors and attitudes toward MMT (see below). They also provided consent to share clinic records and medical test results including drug use and HCV testing as part of the routine intake procedure in Chinese MMT. Staff provided support for participants who may have had challenges with comprehending study procedures or questionnaires. The UCLA Institutional Review Board and two local Institutional Review Boards approved the study. Results from the parent study are reported elsewhere. 19 The current study conducted secondary analyses on 306 patients for whom HCV test results were available (160 from Shanghai and 146 from Kunming). These study participants included 24% female, mean age of 38 (SE ¼ 8) and the majority (68%) did not complete high school.
Instruments/measures
In addition to demographics and drug use history, the following questionnaires were administered during intake.
Risk behavior survey (RBS): an abbreviated version of the risk behavior assessment developed by the National Institute on Drug Abuse (NIDA), it is used to measure risk behaviors related to HIV and HCV. Risk behaviors in the areas of drug use and sex in the previous 30 days are measured. Additional items include whether the sexual partner uses or injects drugs. Reliability and validity assessments of the RBS support its adequacy as a research tool for populations of drug users, including IDUs.
-22
HCV knowledge: measured using a 20-item true/false/don't know set of statements developed by Strauss et al. 23 The items are specifically intended to address HCV-related information that is especially relevant to drug treatment patients. They include items concerning HCV transmission risk and risk behaviors; HCV diagnosis and disease progression; current HCV treatment options (including drug-dependent patients in treatment programs); treatment outcomes if HCV infected; health maintenance if HCV infected; differences between the various types of hepatitis and the availability of vaccines for them; and HIV and HCV co-infection. Attitudes toward methadone: adapted from one described by Schwartz et al. 24 which was originally developed by Brown et al. 25 The instrument assesses attitudes toward methadone, including perceptions of methadone's potential helpfulness, negative physical and cognitive effects associated with methadone and the perceived purpose of methadone administration (e.g. patient concern, crime control). One item (methadone represents an oppression of an African-American minority by a white majority) was irrelevant in China and thus was dropped. Likert scaling was employed such that the respondent had five options, ranging from 'strongly agree' to 'strongly disagree.' A single eight-item subscale examining the medication as an 'aid to behavior change' was derived as well.
Statistical analyses
The analyses included two-by-two ANOVA testing main effects of study site (Shanghai and Kunming), HCV status ( positive versus negative) and the interaction. In addition, logistic regression was conducted to identify predictors of HCV serostatus. In preliminary analyses, we included sexual risks in the logistic regression predicting HCV serostatus. However, many participants (104) did not answer sexual questions. Sexual risk was not a significant predictor, and excluding the sexual risk did not change the findings. Thus, we report results of the regression analyses without the sexual risk indicators. The significant P-value is set at 0.05 or less.
Results
HCV serostatus prevalence
Overall, 53.3% of the subjects tested positive for HCV at the treatment entry, and there was insignificant difference between the two study sites (55.5% in Kunming versus 51.3% in Shanghai). In contrast, in response to the question of having hepatitis (any kind), only 16.9% of the patients in Kunming and 25.3% in Shanghai responded affirmatively. As shown in Table 1 , among those testing positive for HCV, 80% did not know their seropositive status (50.3% thought they did not have any hepatitis, 14.8% never found out their test results and 14.8% were never tested). 
HCV knowledge
The total sample scored, on average, 5.5 items correctly out of 20 in the HCV knowledge assessment, demonstrating extremely limited knowledge about HCV (Table 2) . Overall, there was no difference between HCV negative (5.4) and HCV positive (5.9) groups. On individual knowledge items, the two groups were mostly similar, with HCV-positive individuals demonstrating more knowledge on a few items. More than half of the sample did not know the answer to questions such as 'Hepatitis C infected clients should get vaccinated for hepatitis A and hepatitis B,' or 'Drug users must stop taking methadone before starting HCV medication.' Only about one-fifth of the sample were aware that hepatitis C can be spread when IDUs share their rinse water, and less than half were aware that most new hepatitis C infections are caused by injection drug use.
Risk behaviors
Injection and sexual risk behaviors are provided in Table 3 . On average, participants reported first drug use at the age of 27, with patients in Kunming initiating use at an earlier age of 25 than patients in Shanghai at 28. HCV-positive patients had used opiates for a mean of 12.5 years, which was significantly longer than the 9.7 years of drug use reported by the HCV-negative patients; the significant interaction indicated that this difference was larger among patients in Kunming. Recent injection was also significantly higher among HCV-positive patients, for both Kunming and Shanghai, with significantly more patients in Shanghai engaged in this high-risk behavior than that in Kunming. Overall, few patients reported needle sharing in the past 30 days before entering the treatment. In terms of sexual behaviors, few reported multiple sex partners in both sites. Among those sexually active, significantly more patients in Shanghai than that in Kunming rarely or never used condoms with their primary sex partner, casual partner or commercial sex worker. None of the sexual risks differed between HCV-positive versus HCV-negative patients.
Using logistic regression, we examined predictors of HCV serostatus (see Table 4 ). Controlling for demographics (gender, age, education, marital status and study site), only injection use and length of drug use history were significant predictors of HCV-seropositive status, while HCV knowledge, employment and arrest history were not.
Attitudes toward MMT
The overall score of the attitudes toward the MMT was similar for HCV-positive and HCV-negative patients and across the two study sites (see Table 3 ). Findings for attitudes toward the MMT as aids to behavior change largely parallel the findings for the overall attitudes, with no differences by HCV status or study site.
Discussion
Main finding of this study Similar to findings from studies conducted in the USA 11, 12 and Australia, 16 few HCV-positive IDUs in China were aware of their serostatus. Although the HCV status of participants was identified through antibody screening and we do not have confirmatory results, the risk factors for those who are antibody positive or PCR positive are similar. The importance of knowing one's HCV status and being aware of risky behaviors contributing to HCV infection cannot be overstated. In order for IDUs to understand the need to avoid behaviors that put themselves and others at risk of transmission of HCV (as well as other infectious diseases including HIV), they must have knowledge about HCV. The extremely low level of HCV knowledge among Chinese IDUs revealed by the present study is alarming. On average, the sample scored fewer than 6 items correctly (out of the 20 total), which is considerably lower than findings from other research in the USA using the same instrument (mean of 11.1, SD ¼ 4.1 14 ). Many participants indicated that they did not know the answer to many questions and only about one-fifth of the sample were aware that HCV can be spread when IDUs share their rinse water. Less than half were aware that most new HCV cases are caused by injection drug use. In addition, about one-quarter of our sample were female. In the USA, about 30% of individuals who enter MMT are women, whereas in China 20 -25% of MMT patients are women. It is not known if HCV prevalence is lower among women in China or if there are greater barriers to treatment access, underscoring an area for further research. Along this line, it should also be noted that health promotion efforts are unlikely to be successful if wider determinants of health that prevent people from changing their behavior is not taken into consideration.
What is already known on this topic
Although HCV is being monitored regularly, most clinics do not offer more comprehensive services such as counseling or referral for HCV treatment ( personal communication with clinic staff in Chinese MMT, 2009). Strategies are needed to prevent HCV infection and transmission and to provide access to treatment. Many HCV seropositive individuals remain unaware of their infection until their health is HEPATITIS C METHADONE TREATMENT SHANGHAI KUNMING significantly compromised, when treatment options are severely restricted, and by which time they may have unknowingly transmitted the virus to others. MMT programs should notify patients of their serostatus. Consistent with other studies, we found that recent injection use and length of drug use history predicted HCV serostatus. The limited HCV knowledge among both HCV-positive and HCV-negative patients highlight the need for HCV education, as they are at high risk for contracting and transmitting the virus. In the absence of an imminent prospect of effective vaccines, education and behavioral interventions are needed to reduce risk behaviors that may lead to acquiring or transmitting these diseases. MMT programs are well situated to fill an important HCV education service gap among drug users by providing HCV education to their patients. 14 Augmenting MMT with HCV education and What this study adds
While MMT programs are important platforms for providing services addressing patient problems and needs, patients who have a positive view of MMT may be more willing or likely to initiate or continue participating in MMT. 24 Our study showed that the MMT attitudes among Chinese MMT patients appeared less favorable than attitudes held by MMT patients reported in the American study (M ¼ 93.8, SE ¼ 0.9; using the same instrument) and slightly better than the out-of-treatment sample (M ¼ 80.6, SE ¼ 1.5). 24 The finding for attitudes toward MMT as aids to behavior change (M ¼ 22) indicate a less positive view, compared with American participants (mean of 31.5 for in-treatment sample and 26.9 for out-of-treatment sample). 24 These findings suggest that even among those who entered MMT, Chinese patients had reservations about the medication and they were less able to acknowledge the potential of MMT as an aid to behavior change.
Moreover, almost 80% of study participants were not aware of their HCV serostatus. Most opioid drug users in China have never been tested for HCV prior to MMT treatment entry. Our findings suggest that MMT is an appropriate setting for the identification of HCV infection and linkage to needed counseling and health care.
Limitations of this study
We acknowledge a number of limitations to the study. First, the patients taking part in our research were restricted to patients receiving care in two sites in China, and may not necessarily be representative of MMT patients or the broader population of IDUs nationwide. Still, the two distinctive sites demonstrated similar findings. We focused on MMT patients because HCV testing has already been part of the routine procedures and MMT is best situated to provide education, counseling and treatment referral, if not HCV services directly. (Further study would be necessary to assess morbidity and needs for HCV treatment.) Secondly, we cannot exclude the possibility of reporting bias among drug abusers, especially under-reporting of risk behaviors. Finally, broader determinants of health (e.g. access to healthcare, availability of needle-exchange services, provision of clean rinsing water) likely impact health behaviors and behavioral change, but these were not examined by the current study.
Despite study limitations, the study found significant knowledge gaps in IDUs' knowledge of HCV with respect to transmission risks, diagnosis and disease progression, as well as consequences and options if infected. Education and health promotion messages about HCV for MMT staff and IDUs are urgently needed. Expanding HCV services in MMT can promote the health of chronically HCV-infected IDUs and reduce risk behaviors among injectors susceptible to acquiring or transmitting HCV. 
